ALPS 12
Alternative Names: ALPS-12; RG-6524Latest Information Update: 14 Jun 2023
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Roche
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Apr 2023 Efficacy, pharmacodynamic and adverse event data from in vitro studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research, 2023 (AACR-2023)
- 31 Jan 2023 Phase-I clinical trials in Solid tumours in Switzerland (IV) (Roche pipeline, February 2023)